Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that President and CEO David Cory will present at the Jefferies Global Healthcare Conference on June 8, 2022, at 9:00 AM ET in New York City. The presentation will provide an overview of the company’s innovative therapies aimed at treating hepatitis delta virus (HDV) and other diseases. Investors will also have the opportunity for one-on-one meetings at the conference. A live webcast of the presentation will be accessible on Eiger's website, with a replay available for 90 days.

PALO ALTO, Calif., June 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 9:00 AM ET in New York City. The Company will also host one-on-one meetings with investors at the conference.

A live webcast of the presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com. A replay of the presentation will be available on the website for at least 90 days. 

About Eiger

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from TOGETHER, a Phase 3 investigator-initiated study.

All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com 

Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-301560720.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

When is Eiger BioPharmaceuticals presenting at the Jefferies Global Healthcare Conference?

Eiger BioPharmaceuticals will present on June 8, 2022, at 9:00 AM ET.

Who will represent Eiger BioPharmaceuticals at the conference?

David Cory, President and CEO, will present at the conference.

Where can I watch the Eiger BioPharmaceuticals presentation live?

The presentation will be available via live webcast on Eiger's website.

What is Eiger BioPharmaceuticals focused on?

Eiger is focused on developing therapies for hepatitis delta virus (HDV) and other serious diseases.

What innovative therapies is Eiger BioPharmaceuticals developing?

Eiger is developing first-in-class therapies targeting HDV and peginterferon lambda for COVID-19.